(Q94604906)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918474%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

review article

1 reference

title

Atopic dermatitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918474%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

author name string

Alexander K C Leung

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918474%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

K L E Hon

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918474%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

Wm Lane M Robson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918474%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918474%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

published in

Advances in pediatrics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918474%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918474%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

page(s)

241-273

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918474%20AND%20SRC:MED&resulttype=core&format=json

Managing childhood atopic dermatitis

17 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

New insights into atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Pediatric atopic eczema: the impact of an educational intervention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Managing a common disorder in children: Atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

A treatment approach for atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

7 January 2021

10. Atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

CDLQI, SCORAD and NESS: are they correlated?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Advances in pediatric asthma and atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The relationship between early fever and allergic sensitization at age 6 to 7 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Recent advances in treatment strategies for atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Analysis of familial aggregation of atopic eczema and other atopic diseases by ODDS RATIO regression models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The genetics of atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Atopic dermatitis -- a total genome-scan for susceptibility genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

New concepts in the pathogenesis of atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Lipid abnormalities in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Endogenous antimicrobial peptides and skin infections in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Current management of atopic dermatitis and interruption of the atopic march

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The role of microorganisms in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Staphylococcal exotoxins exert proinflammatory effects through inhibition of eosinophil apoptosis, increased surface antigen expression (CD11b, CD45, CD54, and CD69), and enhanced cytokine-activated oxidative burst, thereby triggering allergic infla

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Staphylococcal Toxins Augment Specific IgE Responses by Atopic Patients Exposed to Allergen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

IgE-sensitization to cellular and culture filtrates of fungal extracts in patients with atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

IgE antibodies to Pityrosporum ovale in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Dendritic cells and fungi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The epidemiology of atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Role of intestinal flora in the development of allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Role of food allergy in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Atopic dermatitis: Clinical relevance of food hypersensitivity reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Food sensitivity and the pathogenesis of atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Late eczematous reactions to food in children with atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Food allergy and atopic dermatitis in infancy: an epidemiologic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Induction of atopic dermatitis by inhalation of house dust mite

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The effect of environmental tobacco smoke on eczema and allergic sensitization in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

7 January 2021

Atopic dermatitis update

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Position paper on diagnosis and treatment of atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Allergic contact dermatitis in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison with healthy controls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Suggestions regarding a more appropriate understanding of atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Atopic dermatitis in infants and children. An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Development of Atopic Dermatitis During the First 3 Years of Life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Clinical features and diagnostic criteria of atopic dermatitis in relation to age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Hanifin's and Rajka's minor criteria for atopic dermatitis: Which do 2-year-olds exhibit?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Frequency and significance of minor clinical features in various age-related subgroups of atopic dermatitis in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Consensus conference on pediatric atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Consensus guidelines in diagnosis and treatment of atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Lesson from performing SCORADs in children with atopic dermatitis: subjective symptoms do not correlate well with disease extent or intensity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The development of an objective method for measuring scratch in children with atopic dermatitis suitable for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Nocturnal wrist movements are correlated with objective clinical scores and plasma chemokine levels in children with atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Assessing itch in children with atopic dermatitis treated with tacrolimus: objective versus subjective assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The Nottingham Eczema Severity Score: preliminary refinement of the Rajka and Langeland grading

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Validation of a self-administered questionnaire in Chinese in the assessment of eczema severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Serum concentration of macrophage-derived chemokine may be a useful inflammatory marker for assessing severity of atopic dermatitis in infants and young children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Serum levels of cutaneous T-cell attracting chemokine (CTACK) as a laboratory marker of the severity of atopic dermatitis in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Urinary leukotriene E4 correlates with severity of atopic dermatitis in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Serum concentration of IL-18 correlates with disease extent in young children with atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Plasma TARC concentration may be a useful marker for asthmatic exacerbation in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Quality of life and disease severity are correlated in children with atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Life quality assessment among patients with atopic eczema.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Development of the Childhood Atopic Dermatitis Impact Scale: initial validation of a quality-of-life measure for young children with atopic dermatitis and their families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

International development of the Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The quality of life of parents of children with atopic dermatitis: interpretation of PIQoL-AD scores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The differential diagnosis of atopic dermatitis in childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Pediatric atopic dermatitis: should we treat it differently?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Effects of atopic dermatitis on young American children and their families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Factors promoting psychological adjustment to childhood atopic eczema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Resting energy expenditure, oxygen consumption and carbon dioxide production during sleep in children with atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The burden of atopic dermatitis: impact on the patient, family, and society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The psychosocial burden of childhood atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Atopic dermatitis is associated with a decrement in health-related quality of life.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Allergy workup: when and how for the child with atopic dermatitis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Patterns of food hypersensitivity during sixteen years of double-blind, placebo-controlled food challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Lessons from atopy patch testing in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Steroid fears in children with eczema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Patient perspectives on the management of atopic dermatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Food hypersensitivity and atopic dermatitis: evaluation of 113 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Dietary restriction and supplementation in children with atopic eczema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Guidelines of care for atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Dietary prevention of allergic diseases in infants and small children. Part III: Critical review of published peer-reviewed observational and interventional studies and final recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Atopic dermatitis prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life: the German Infant Nutritional Intervention Study, a randomized double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

A survey of bathing and showering practices in children with atopic eczema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The role of topical calcineurin inhibitors in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Tacrolimus ointment: its place in the therapy of atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Atopic eczema is associated with delayed maturation of the antibody response to pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Topical immunomodulators for atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Tacrolimus and pimecrolimus for atopic dermatitis: where do they fit in?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Tacrolimus: focusing on atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

7 January 2021

Pruritus in children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Silver-coated textiles in the therapy of atopic eczema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Coated textiles in the treatment of atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Use of textiles in atopic dermatitis: care of atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

New aspects of probiotics--a novel approach in the management of food allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Probiotics and food-allergic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Two "positive" studies of probiotics for atopic dermatitis: or are they?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Oral administration of probiotic Escherichia coli after birth reduces frequency of allergies and repeated infections later in life (after 10 and 20 years).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Effect of probiotic Lactobacillus strains in children with atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Effects of probiotics on atopic dermatitis: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Brief case series: montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

A pentaherbs capsule as a treatment option for atopic dermatitis in children: an open-labeled case series.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

One-year follow up of children treated with Chinese medicinal herbs for atopic eczema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Herbal creams used for atopic eczema in Birmingham, UK illegally contain potent corticosteroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Efficacy and tolerability of borage oil in adults and children with atopic eczema: randomised, double blind, placebo controlled, parallel group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

Clinical practice. Atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.013

10.1016/J.YAPD.2007.03.013

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918474%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

1 reference